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Abstract 
FOXP3 (forkhead box P3) polymorphism is associated with many inflammatory diseases and cancers. Acute 
lymphoblastic leukemia (ALL) is the most common type of pediatric malignancies.This study was designed to 
investigate the impact of FOXP3 (-3279C/A and -2383C/T) gene polymorphism on the susceptibility of 
Egyptian children to ALL. A total of 128 subjects with ALL and 124 healthy controls were enrolled in this 
study. Genotyping of FOXP3 (-3279C/A and -2383C/T) were performed by polymerase chain reaction 
restriction fragment length polymorphism (PCR-RFLP). There was a significant increase (P<0.01) in FOXP3 (-
3279CC) genotype, while FOXP3 -3279CA genotype was significantly decreased in ALL patients compared to 
controls. Insignificant change in FOXP3 (-2383C/T) genotypes was demonstrated between both groups. FOXP3 
(-2383CC) genotype was significantly decreased (p<0.05) in treatment responders compared to non-responders 
and a significant increased (p<0.05) in relapsed patients comparing to the non-relapsed group. Taken together, 
our pilot study pointed to the potential role of FOXP3 (-3279C/A) gene polymorphisms in Egyptian children 
ALL susceptibility. An additional prospective large scale study should be carried out to support our findings. 
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1. Introduction  
Pediatric hematopoietic leukemia is one of the highest mortality rates throughout the globe [1]. Acute 
lymphoblastic leukemia (ALL) is the most common type of pediatric hematopoietic leukemia in children, 
accounting for 30-35% of all pediatric cancers [2,3]. It represents the 11
th
 and 10
th
 most frequent cause of cancer 
occurrence and death worldwide; respectively [4].  Regulatory T cells (Tregs) were defined as 
immunosuppressive CD4‏+ T cells expressing CD25+ on their surface [5]. They are characterized by the 
expression of the transcription factor forkhead box P3 (FOXP3) [6]. They are reported to be associated with 
tumor progression and reduced survival in cancer patients [7,8]. In leukemia, Tregs are reported to have a dual 
role either by suppressing anti-tumor immune responses mediated by T-cells or regulating the malignant 
immune cell, directly or by interfering with T-cell help [9]. FOXP3, the master transcriptional activator for 
Tregs, is important for its development and maintenance of function [10,11]. FOXP3 gene; 1296 bp in size, is 
located at the short arm of the X-chromosome (Xp11.23) and consisted of 11 exons encoding a protein of 431 
amino acids and 3 non-coding exons [12].  Single nucleotide polymorphisms (SNPs) in the FOXP3 gene might 
change its expression level and impair the suppressive function of Tregs [13]. In the promoter region of FOXP3, 
there are five SNPs: -924A/G (rs2232365), -1383C/T (rs2232364), -2383C/T (rs3761549), -3279C/A 
(rs3761548) and -3499A/G (rs3761547) [14]. Two of them (-3279C/A and -2383C/T) have been reported to be 
associated with cancer risk [13, 15]. In the light of the vital role of Treg cells in cancer, the current study is 
performed to investigate the genetic association between FOXP3 (-3279C/A) and (-2383C/T) gene 
polymorphism and susceptibility to ALL in the Egyptian children. 
2. Subjects and Methods 
2.1 Patients and controls 
This study consisted of 128 Pediatric ALL patients with a mean age of 7.18 ± 0.38 collected from the 
Department of pediatric oncology at South Egypt Cancer Institute and Hospital, Assiut University, Egypt. They 
were categorized by risk depending on the assignment protocol [16]. The patient’s hematological, biochemical 
data and immunophenotyping were recorded from pediatric ALL files with the help of the medical oncologist 
during follow up. Treatment based on Total XIIIB regimen [17]. One hundred and twenty-four age- and sex-
matched donors' healthy individuals free of any chronic diseases and without a family history of leukemia were 
included as control individuals. The blood samples of healthy individuals used in the present study were part of 
the samples taken for clinical diagnostic tests in the hospital. All protocol investigations were done in 
accordance with the Human Ethical Clearance Committee guidelines for Clinical Researches according to 
Helsinki Declaration (1964) and performed with the understanding of the human subject. Research approved by 
the Ethical Clearance Committee (http://www.aun.edu.eg/faculty-medicine/Ethical Committee.php) at South 
Egypt Cancer Institute and Hospital, Assiut University (IORG: IORG0006563 and IRB: IRB00007877).  
Informed consent was obtained from a parent and/or legal guardian for every patient before blood collection and 
the ethics committee/institutional review board has approved the consent procedure. 
2.2 DNA Isolation 
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From each individual, 3 ml venous blood was collected on ethylene-diamine-tetra-acetic acid (EDTA) sterile 
vacutainer. Genomic DNA was extracted from whole blood samples by the GentraPuregene Blood Kit (Qiagen 
Company, Hilden, Germany) according to the manufacturer’s instructions. Extracted DNA was applied to 1% 
agarose gel electrophoresis to confirm its integrity. The concentration of DNA in all samples was measured by 
using a nanodrop 2000c (Thermo Fisher Scientific, Waltham, MA, USA). 
2.3 Genotyping of FOXP3 
FOXP3 (-3279C/Aand -2383C/T) primer sequences and DNA fragments characterizing each genotype/allele 
were summarized in Table (1). Genotyping of FOXP3 (-3279C/A and -2383C/T) were performed by PCR-based 
restriction fragment length polymorphism (PCR-RFLP) method as previously described [15, 18]. The reaction 
was performed in one tube with a final reaction volume of 25 μl. PCR mixtures consisted of 2x DreamTaq 
Green Master Mix (Fermentas, Thermo Fisher Scientific Inc.), 10pmoles of each primer, and 200 ng of DNA. 
All polymerase chain reactions (PCR) were performed in 2720 thermal cycler (Applied Biosystems). The 
amplification conditions for -3279C/A were: 5 minutes at 94°C and 30 cycles of denaturing for 30s at 94°C, 
annealing for 30s at 68°C and extension for 30s at 72°C then a single final extension for 10 minutes at 72°C. For 
-2383C/T, initial denature at 95°C for 3 minutes followed by 30 cycles (denaturing at 94°C for 30s, annealing at 
60°C for 30s, and extension at 72°C for 1 minutes) then single final extension at 72°C for 10 minutes was 
performed. Using proper restriction enzyme, PCR products were digested and visualized by 4% agarose gel 
electrophoresis in 0.5X Tris-acetate-EDTA (TAE) buffer with ethidium bromide staining (10 mg/ml). The PCR 
products/fragments were estimated by comparing them with 100bp/25bp DNA ladder (Fermentas). 
2.4 Statistical analysis 
Statistical analysis was performed using the Statistical Package for Social Science (SPSS) version 21 (IBM 
Corporation, USA). Comparisons between both groups were performed by independent T-test, and the results 
were presented as the mean ± standard error. Categorical variables were presented as frequencies (%). Chi-
squared (X
2
) tests were performed to compare allele, genotype and haplotype distribution. The odds ratio (OR) 
and 95% confidence intervals (CI) were calculated to measure the relative risks in both control and ALL 
patients.  
Table 1: Primers used in the genotyping of FOXP3 SNPs 
The correlation between variables was determined using Spearman’s correlation test. The online tool SNPstats 
(https://www.snpstats.net/start.htm) was used to perform haplotype reconstruction from population genotype 
Position Primer sequence PCR 
Product 
 Enzyme   Restriction product 
FOXP3 
-3279C/A 
(rs3761548) 
Forward:   5′-CCTCTCCGTGCTCAGTGTAG-3′. 
Reverse:    5′-CTCACCTAGCCCAGCTCTTG-3′. 
300 bp PstI CC: 300bp 
CA:300/159/ 141 bp 
AA:159/141 bp 
 -2383C/T 
(rs3761549) 
Forward:    5′-GCCTGGCACTCTCAGAGCTT-3′. 
Reverse:     5′-GTCTGTGGAGGCTCCGAACA-3′. 
942 bp BsrI CC:528/213/164 bp 
CT:565/377/213/164 bp 
TT:565/377 
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data and Linkage Disequilibrium (LD) parameters (D′ andr2). All values were two-tailed, and 𝑃 values <0.05 
were considered to be statistically significant. 
3. Results 
3.1  Patients’ characteristics 
The demographic, hematological and biochemical characteristics of pediatric ALL patients and healthy controls 
enrolled in this study are summarized in Supplementary Table (1) while clinical characteristics of ALL patients 
are presented in Supplementary Table (2). 
3.2 Association between FOXP3polymorphism and ALL  
Genotype distribution and allelic frequency of FOXP3 SNPs (-3279C/A and-2383C/T) in ALL patients and 
healthy subjects were presented in Table (2). Analysis of FOXP3 -3279C/A polymorphism revealed that -
3279CC genotype was the most frequent genotype in female patients while -3279CA genotype was the most 
frequent one at female controls. Comparing with female controls showed a significant increase (p<0.01) in -
3279CC genotype and a significant decreased (p<0.001) in -3279CA genotype in female patients. In both 
genders, the -3279C allele was more frequent in pediatric ALL children compared to A allele. No statistically 
significant difference in allele frequency between patients and controls. FOXP3 -3279CC and AA genotype 
could be considered as risk factors for ALL (OR= 3.07; OR=1.66; respectively) and -3279CA genotype might 
be a protective genotype (OR=0.27). After the segregation of patients and controls, the -3279C allele might be 
considered as a risk factor for the disease in female (OR= 1.26) and male (OR= 1.13) patients. On the other side, 
the -3279A allele might be considered as a protective factor from pediatric ALL in females (OR=0.79) and 
(OR=0.87) in males.  Genotyping of FOXP3 -2383C/T showed that the CT genotype and C allele were the most 
frequent while the TT genotype and T allele were the least in both groups. Insignificant change in the 
distribution of all genotypes/alleles between patients and control groups was demonstrated. -2383CT genotype 
(OR= 1.72) in females and C allele (OR= 1.26) in males could be considered as risk factors for ALL. Haplotype 
frequencies of the FOXP3 (-2383C/T) and (-3279C/A) SNPs in ALL patients and controls were summarized in 
Table (3). Four haplotypes were emerged (CC, CT, AC and AT) from the estimates of haplotype frequencies. 
The highest frequency of haplotypes in ALL patients group was CC. Insignificant change in haplotype 
distribution was demonstrated between both groups/genders. The haplotype estimates (D'=0.053, r
2
=0.001) for 
males and (D'=0.085, r
2
=0.006) for females indicate the absence of LD between FOXP3 (-2383C/T and -
3279C/A) in the Egyptian population. 
 
 
  
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2020) Volume 53, No  2, pp 159-170 
 
163 
 
Table 2: Demographic, hematological and biochemical characteristics of ALL patients and healthy controls. 
Laboratory 
Investigations 
Control group 
(N=124) 
(Mean± SE) 
ALL  group 
(N=128) 
(Mean±  SE) 
P-value  
Demographic Data     
Age (year) 6.67 ± 0.30 7.18 ±0.38 NS  
Gender (M/ F) 58/66 44/84 NS  
Hematological Data     
WBCs (10
3
/µL) 8.04 ± 0.18 46.53 ± 6.60 P<0.001  
Hemoglobin (g/dl) 11.49 ± 0.11 8.15 ± 0.21 P<0.001  
PLT (10
3
/µL) 316.76 ± 5.94 81.60 ± 7.40 P<0.001  
Biochemical Data     
AST (IU/L) 25.16 ± 0.60 43.65 ± 5.71 P<0.01  
ALT (IU/L) 22.56 ± 0.45 32.24 ± 3.72 P<0.01  
ALB (g/L) 43.72 ± 0.41 36.00 ± 1.17 P<0.001  
Bilirubien (mg/dl) 0.66 ± 0.01 0.86 ± 0.25 NS  
Urea (mg/dl) 24.33 ± 0.75 38.98 ± 15.56 NS  
Creatinine  (mg/dl) 0.35 ± 0.01 0.61 ± 0.16 NS  
LDH (IU/L) 305.52 ± 4.44 1803.71 ± 217.98 P<0.001  
Sodium (mEq/L) 137.26 ± 0.17 130.82 ± 2.70 NS  
Potasium (mEq/L) 4.25 ± 0.03 4.61 ± 0.41 NS  
Calcium (mg/dl) 9.37 ± 0.04 9.21 ± 0.13 NS  
All data are presented as mean ± SE. WBCs: White blood cells, PLT: Platelet, AST: Aspartate aminotransferase, 
ALT: Alanine aminotransferase, ALB: Albumin, LDH: Lactate dehydrogenase, IU/L: International Units per 
liter, g/L: Gram per liter, mg/dL: Milligrams per Deciliter, mEq/L: MilliequivalentsPerLitre, NS: not significant. 
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Table 3: Clinical characteristics of ALL patients 
Data Total patients  
(N=128)  N (%) 
WBC  
Low risk <50,000/Ml 89 (69.5%) 
High risk  >50,000/Ml 39 (30.5%) 
Age at diagnosis  
Low risk 1-10 years 75 (58.6%) 
high risk >10 years 53 (41.4%) 
Response for treatment 
Responders 98 (76.6%) 
Non responders 30 (23.4%) 
Immunophenotype  
B-ALL 107 (83.6%) 
T-ALL   21 (16.4%) 
Relapse  
No relapse 102 (79.6%) 
Relapsed  26 (20.4%) 
Outcome  
Alive 118 (92.2%) 
Dead 10 (7.8%) 
CNS II  
Yes 83 (72.8%) 
No 31 (27.2%) 
CNS III  
Yes 42 (40.8%) 
No 61 (59.2%) 
Table 4: Genotype distribution and allelic frequency of the FOXP3 SNPs (-2383C/T,and -3279C/A) in controls 
and ALL patients 
Position Control group 
(N=124) 
ALL group 
(N=128) 
OR (95% CI ) P-value 
 
-3279C/A (rs3761548) (N,%) 
 Female (66) Female (84)   
C/C 11 (17%) 32 (38%) 3.07 (1.40 - 6.73) P<0.01 
C/A 41 (62%) 26 (31%) 0.27 (0.13 - 0.53) P<0.001 
A/A 14 (21%) 26 (31%) 1.66 (0.78 - 3.52) NS 
CA/AA 55 (83%) 52 (74%) 0.32 (0.14 - 0.71) P<0.01 
C 63 (48%) 90 (54%) 1.26 (0.80 - 1.99) NS 
A 69 (52%) 78 (46%) 0.791 (0.50 - 1.24) NS 
 Male (58) Male (44)   
C 73 (63%) 58 (66%) 1.13 (0.63 – 2.03) NS 
A 43 (37%) 30 (34%) 0.87 (0.49 - 1.56) NS 
-2383C/T (rs3761549) (N,%) 
 Female (66) Female (84)   
C/C 20 (30%) 21 (25%) 0.76 (0.37 - 1.57) NS 
C/T 34 (52%) 51 (61%) 1.45 (0.75 - 2.79) NS 
T/T 12 (18%) 12 (14%) 0.75 (0.31 - 1.79) NS 
CT/TT 46 (70%) 63 (67%) 1.30 (0.63 - 2.68) NS 
C 74 (56%) 93 (55%) 0.97 (0.61 - 1.53) NS 
T 58 (44%) 75 (45%) 1.02 (0.65 - 1.62) NS 
 Male (58) Male (44)   
C 61 (53%) 51 (58%) 1.26 (0.72 - 2.20) NS 
T 55 (47%) 37 (42%) 0.79 (0.45 - 1.37) NS 
P: p value (significant), NS: Not significant 
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Table 5: Haplotype frequencies of the FOXP3 SNPs (-2383C/T and -3279C/A)in controls and ALL patients 
Haplotype Gender Control group Patients group OR ( 95% CI ) P-value 
 
CC Female 25.2% 33.6% 1.00 ---- 
 male 32.2% 41.5% 1.00 ---- 
 
CT female 22.4% 21.7% 0.52 (0.24 – 1.14) NS 
 male 30.7% 24.3% 0.58 (0.28 – 1.20) NS 
 
AT female 21.4% 24.6% 0.91 (0.47 – 1.76) NS 
 Male 16.7% 16.3% 0.70 (0.35 – 1.39) NS 
 
AC Female 30.7% 19.9% 0.66 (0.28  – 1.55) NS 
 Male 20.3% 17.7%       0.79 (0.40 – 1.56) NS 
P: p value (significant), NS: Not significant  
3.3 Association between FOXP3 SNPs and ALL clinical manifestation 
Associations of the most common clinical findings of the disease and FOXP3 gene polymorphisms in ALL 
patients were presented in Table (4). Analysis of FOXP3 (-3279C/A) revealed that -3279CC genotype was 
significantly increased (p<0.05) and CA was significantly decreased (p<0.001) in patients' high age risk 
compared those with low risk. On the other side, the -3279CA genotype showed a significant reduction (p<0.05) 
in relapsed patients compared to non-relapsed ones. Moreover, results of FOXP3 (-2383C/T) SNP pointed that 
CC genotype was significantly decreased (p<0.05) in treatment responders compared to non-responders and a 
significant increased (p<0.05) in relapsed patients comparing to the non-relapsed group. 
4. Discussion 
FOXP3 is an immunological regulator and is involved in the regulation, activation and differentiation of 
regulatory T cells [19]. The absence of a functional FOXP3 gene product might result in an abnormal 
production of Treg cells [20]. FOXP3 polymorphisms have been investigated as candidate risk factors in 
autoimmune diseases and various tumors [21]. Several studies investigated the association between the FOXP3 
promoter polymorphisms (-3279C/A and-2383C/T) and the risk of cancer [15, 19, 21]. In the current work, 
analysis of FOXP3 -3279 C/A polymorphism revealed that -3279CC genotype is the most frequent in ALL 
female patients with a significant decrease in CA genotype compared to female controls. The C allele is more 
frequent over A allele in both genders in the patient group compared to the control group. Thus, FOXP3 -
3279CC and AA genotypes might be considered as risk factors for ALL in females. In accordance with these 
results, Piao and his colleagues [21] reported -3279CC genotype as a risk factor in the development of hepatic 
veno-occlusive disease after allogeneic hematopoietic stem cell transplantation suggesting this SNP to be 
considered as a candidate marker for predicting the severe complications after allogeneic hematopoietic stem 
cell transplantation for pediatric ALL patients. In other types of cancer, conflicting results about the role of 
FOXP3 gene polymorphism in neoplastic cells were demonstrated. The AA genotype and A allele were 
associated with a higher risk of prostate cancer incidence [22]. The meta-analysis results of Cheng and his 
colleagues [13] and Chen and his colleagues [23] stressed on the importance of -3279C/A SNP and its 
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association with increased cancer risk in various types of malignancies. In disagreement with these results, 
Cezar‑ dos‑ Santos and his colleagues [24] in the Brazilian population, reported that-3279AA genotype may 
exert a protective role against human papilloma virus infection in females. Concerning other diseases, the C 
allele is over A allele in patients with multiple sclerosis, although AA genotype and A alleles might be 
considered as risk factors for the disease in the Southern Brazilian population [25]. In agreement to this results, -
3279A allele was found to be predisposed to the development of late acute cellular rejection and ulcerative 
colitis [26-27]. Controversy, no allelic association of-3279C/A SNP was observed with autoimmune thyroid 
disease and Crohn’s disease susceptibility in South-Indian and Chinese population; respectively [28-29]. In the 
Egyptian population, a statistically significant increase in -3279CC genotype and C allele was previously 
recorded in patients compared to controls, suggesting that this SNP may increase the susceptibility of Psoriasis 
Vulgaris [30]. On the other hand, the current study showed that FOXP3 -2383CT genotype and C allele were the 
most frequent in the patient group compared to other genotypes (CC, TT)  and T allele with a significant 
increase in FOXP3 -2383CT genotype in ALL patients compared to controls. This study suggested that -
2383CT genotype in females and C allele in males to be considered as risk factors for ALL in children. This 
SNP was investigated in leukemia patients after allogeneic hematopoietic stem cell transplantation [31]. -
2383TT genotype was found to be in higher frequencies comparing to other genotypes suggesting this genotype 
as an independent risk factor for the occurrence of acute Graft-versus-host disease as a complication after 
transplantation. -2383 CT and TT genotypes were reported to be associated with a higher risk of developing 
brain tumors in Iranian patients [32]. Insignificant change in the distribution of all genotypes of FOXP3 -
2383C/T between Hepatocellular Carcinoma patients and control was previously demonstrated in the Egyptian 
population [15]. Supporting to the previous data, the meta-analysis of Chen and his colleagues [23] pointed out 
that FOXP3 -2383C/T polymorphism was not associated with increased cancer risk in the Chinese population. 
In autoimmune thyroid disease and Crohn’s disease, no allelic association of -2383C/T SNP with susceptibility 
to diseases was reported in the South-Indian population [28]. Polymorphisms in FOXP3 could affect binding 
capability for transcription factors and, hence, FOXP3 expression and Treg function [33]. Interestingly, Nam 
and his colleagues [31] pointed that -2383C/T SNP is situated in a DNA binding site for activating enhancer-
binding protein 4 (AP4), and it is predicted that SNP in FOXP3 -2383C/T will lead that AP4 cannot bind to 
DNA with the T allele of -2383C/T SNP. Therefore, although the understanding of the molecular mechanism of 
AP4 and FOXP3 in Tregs is limited, the modification of AP4 binding affinity in individuals homozygous for -
2383T allele may induce less clonal expansion of Tregs and relative proliferation of effector lymphocytes.The 
findings of this study have to be seen in light of some limitations. The primary limitation to the generalization of 
these results is the sample size. Further study including larger sample size is important to improve our data. 
Although limited studies on pediatric ALL helped us to identify new gaps in the prior literature, it emphasized 
the need for further development in the area of this disease. 
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Table 6:  Association of the most common clinical findings of the disease and FOXP3&ROR-γ gene polymorphisms in ALL patients 
 WBCs –risk Age risk Response ALL-Type Relapse CNSII CNSIII 
 Low High Low High Yes No B-cell T-cell Yes No Yes No Yes No 
 83 35 75 53 98 30  107 21 26 102 83 31 42 61 
 FOXP3 (-3279C/A) (rs3761548) 
CC 38 
45.8% 
16 
45.7% 
28 
37.3% 
30* 
56.6% 
44 
44.9% 
13 
43.3% 
46 
43.0% 
12 
57.1% 
12 
46.2% 
46 
45.1 
36 
43.4% 
16 
51.6% 
19 
45.2% 
30 
49.2% 
CA 20 
24.1% 
8 
22.9% 
28*** 
37.3% 
4 
7.5% 
21 
21.4% 
12 
40.0% 
29 
27.1% 
3 
14.3% 
12* 
46.2% 
20 
19.6% 
21 
25.3% 
8 
25.8% 
11 
26.2% 
14 
23.0% 
AA 
 
25 
30.1% 
11 
31.4% 
19 
25.3% 
19 
35.8% 
33 
33.7% 
5 
16.7% 
32 
29.9% 
6 
28.6% 
2 
7.7% 
36** 
35.3% 
26 
31.3% 
7 
22.6% 
12 
28.6% 
17 
27.9% 
 FOXP3 (-2383C/T) (rs3761549) 
CC 
 
18 
21.7% 
11 
31.4% 
24 
32% 
10 
18.9% 
21* 
21.4% 
13 
43.3% 
26 
24.3% 
8 
38.1% 
12* 
46.2% 
22 
21.6% 
23 
27.7% 
6 
19.4% 
13 
31.0% 
10 
16.4% 
CT 53 
63.9% 
18 
51.4% 
40 
53.3% 
36 
67.9% 
62 
63.3% 
14 
46.7% 
66 
61.7% 
10 
47.6% 
12 
46.2% 
64 
62.7% 
48 
57.8% 
20 
64.5% 
22 
52.4% 
42 
68.9% 
TT 12 
14.5% 
6 
17.1% 
11 
14.7% 
7 
13.2% 
15 
15.3% 
3 
10.0% 
15 
14.0% 
3 
14.3% 
2 
7.7% 
16 
15.7% 
12 
14.5% 
5 
16.1% 
7 
16.7% 
9 
14.8% 
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5. Conclusion 
In conclusion, our preliminary data throws light on the potential role of FOXP3 (-3279C/A) gene 
polymorphisms in ALL susceptibility in Egyptian children. Analysis of selected SNPs denotes that FOXP3 -
3279CC, AA genotype, -3279C allele, and -2383CT genotype in female patients in addition to -2383C allele in 
males are considered as a risk factor for ALL in Egyptian population. Taking a deep look into clinical 
manifestations of the diseases, FOXP3 -2383CC genotype showed a remarkable decrease in treatment responder 
patients and an increase in relapsed ones. Collectively, the study results might help in understanding the FOXP3 
genetic predisposition in pediatric ALL subjects which could affect their immunological status and the 
implication of these detected mutations in ALL risk. 
6. Recommendations 
We highly recommended to conduct further study on larger sample size and to consider measurement of FOXP3 
protein expression. More clarification in the role of FOXP3 polymorphisms in controlling the expression of 
FOXP3 in ALL patients and its correlation with the detected mutation is quite important. 
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